loading page

Malignancy history affected the prognosis of COVID-19 patients via release of Interleukin-6
  • +4
  • Xiaowu Shi,
  • Jiahao Hu,
  • Haixia Ding,
  • Shenglan Ye,
  • Guoxing Xu,
  • Xiuwen Yang,
  • Liangchao Wang
Xiaowu Shi
Huazhong University of Science and Technology Tongji Medical College
Author Profile
Jiahao Hu
Huazhong University of Science and Technology Tongji Medical College
Author Profile
Haixia Ding
Wuhan University Zhongnan Hospital
Author Profile
Shenglan Ye
Huazhong University of Science and Technology Tongji Medical College
Author Profile
Guoxing Xu
Huazhong University of Science and Technology Tongji Medical College
Author Profile
Xiuwen Yang
Huazhong University of Science and Technology Tongji Medical College
Author Profile
Liangchao Wang
Huazhong University of Science and Technology Tongji Medical College
Author Profile

Abstract

Background: Coronavirus disease 2019 (COVID-19), a newly erupted respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has swept across the most of countries. The laboratory characteristics of COVID-patients accompanied with cancer and the risk factors for disease progression and survival of this particular population were few reported. Methods: We enrolled 585 confirmed COVID-19 patients admitted to our hospitals with measured interleukin-6 level on admission. Laboratory tests and outcome were extracted from electronic medical records. Data was divided to cancer group and non-cancer group to explorer the risk factors of progression and survival. Findings: A total of 44 patients with different cancer type (cancer group) and 487 patients without cancer (non-cancer group) were included. Cancer group had significant higher levels of NEUT, NLR, IL-6, and CRP than non-cancer group, but lymphocyte count and ALB were lower. Cancer group showed significantly higher progression rate (42·1% vs 22·5%) and mortality (27·27% vs 11·91%) than non-cancer group. Elevated IL-6 and CRP were the risk factors associated with progression among moderate patients and death in-hospital (all p<0·05) in non- cancer group. This correlation was not observed in caner group. Interpretation: IL-6, CRP, NEUT, and NLR were elevated in COVID-19 patients with cancer, with lower level of LYMP and ALB. IL-6 and CRP were positively correlated with progression and poor outcome in patients without cancer. As one of combined diseases, despite malignancy history did not directly affect the prognosis of COVID-19, but it could play a role in the poorer outcome through release of IL-6 and CRP.